Clinical trial
A Randomized, Patient and Investigator Blinded, Placebo Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With Non-alcoholic Steatohepatitis (NASH)
NCT02913105 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Patient and Investigator Blinded, Placebo Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With Non-alcoholic Steatohepatitis (NASH)
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- October 24, 2016
- Completion date
- September 19, 2018
- Enrollment
- 122 (actual)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.
non-alcoholic steatohepatitis nash